← Leaderboards
Rebecca Marsh
Cincinnati Childrens Hosp Med Ctr
$1,164,079
Attributed
$4,028,417
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,028,417 · 3
By mechanism
R24$3,580,422 · 1
R01$297,995 · 1
R03$150,000 · 1
Top collaborators
- Christopher Craig Dvorak3 shared
- Elie Haddad3 shared
- Troy R Torgerson3 shared
- Michael Wagner3 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Michael Jordan$6,618,086
- Michael Wagner$12,710,656
- Parinda A. Mehta$3,328,864
Others in their field
Top investigators on “Bone Marrow Transplantation”
- Charles A Coltman · Southwest Oncology Group$143,196,322
- Mary M Horowitz · Medical College Of Wisconsin$136,789,389
- Richard L Schilsky · University Of Chicago$50,742,272
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$48,601,153
- Kenneth C Anderson · Dana-Farber Cancer Inst$34,098,561
- Bruce R. Blazar · University Of Minnesota$32,866,133
Research focus
Bone Marrow TransplantationImmunityChildGenotypeNatural HistoryResourcesFutureCellsGenesLifeCongenital ImmunodeficiencyT-LymphocytePhysiciansTransplantation TherapyRecommendationCaringMonitorEnsureClinical CareEnrollmentPatient-Focused OutcomesBaseAutoimmune DiseasesCell Therapy
Grant awards (6)
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity$1,743,065
R24 · FY2025 · AI
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity$21,475
R24 · FY2025 · AI
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity$1,815,882
R24 · FY2024 · AI
Precision Alemtuzumab Therapy in Allogeneic HCT$297,995
R01 · FY2022 · HD · contact PI
Investigations into XIAP-deficient X-linked Lymphoproliferative Disease$75,000
R03 · FY2009 · AI · contact PI
Investigations into XIAP-deficient X-linked Lymphoproliferative Disease$75,000
R03 · FY2008 · AI · contact PI